RESEARCH AND EDUCATION DISCLAIMER
This article summarizes published scientific research for educational purposes only. Level Up Peptides products are intended exclusively for laboratory research by qualified researchers and are not for human or veterinary use. Discussion of published animal or human studies does not recommend those uses or establish the safety or effectiveness of any product sold on this website. This article does not provide medical advice, dosing guidance, or administration instructions.
SUMMARY
ADAMAX is discussed in connection with Semax-related peptide research, but evidence specific to ADAMAX remains difficult to establish. The literature search conducted for this article did not identify a peer-reviewed experiment directly testing ADAMAX. Published Semax studies provide background on research involving nerve-cell signaling and laboratory models, but they cannot establish ADAMAX’s biological activity, stability, safety, or effectiveness. Understanding that distinction is essential when evaluating claims about this research compound.
WHAT IS ADAMAX?
ADAMAX is a name associated with the broader family of ACTH-related peptide products. A 2025 Medsafe document mentions ADAMAX alongside Semax in its discussion of this group. That document establishes that the name is recognized in this context; it is not an experimental study demonstrating ADAMAX’s properties. [1]
A research name alone does not fully identify a material. To connect a supplied compound with a scientific publication, researchers need a documented chemical structure and analytical evidence establishing what was tested. This article does not assign ADAMAX a definitive sequence, molecular weight, or mechanism without a verified source supporting those details.
ARE THERE PUBLISHED STUDIES DIRECTLY TESTING ADAMAX?
Searches conducted for this article using ADAMAX with peptide and Semax terms, along with searches for adamantane-modified Semax, did not identify a directly relevant peer-reviewed experimental publication.
This is a finding from a focused literature search, not proof that no relevant work could exist under another name or outside the sources searched. It does mean that this review cannot substantiate claims that ADAMAX improves memory, increases brain growth factors, persists longer than Semax, or reaches brain tissue more effectively.
The studies below concern Semax. They are included as background and should not be cited as ADAMAX studies.
WHAT DID SEMAX RESEARCH FIND ABOUT BDNF?
A 2006 study by Dolotov and colleagues examined Semax in rats. The investigators measured changes in brain-derived neurotrophic factor, commonly called BDNF, and its associated receptor, TrkB, in the hippocampus. BDNF is a protein involved in nerve-cell signaling. The study reported increases in selected BDNF and TrkB measurements following Semax exposure. [2]
These findings help explain why Semax has attracted interest in neuroscience research. However, the experiment tested Semax in rats, not ADAMAX. It did not establish that a chemically modified derivative would produce the same results. Changes in these biological measurements also should not be presented as proof of improved human memory or intelligence.
WHAT DID OTHER SEMAX LABORATORY RESEARCH EXAMINE?
A 2022 study investigated how Semax affected amyloid-beta aggregation, a process in which protein fragments collect into larger structures. The researchers used laboratory assays, including artificial membrane models, to examine interactions involving Semax, amyloid-beta, and copper. They reported that Semax altered aggregation under the tested conditions. [3]
This was research into molecular behavior in experimental systems. It did not demonstrate treatment or prevention of a neurological disease in people, and it did not test ADAMAX. Its relevance here is to illustrate the kinds of questions studied with Semax, rather than to establish properties of another compound.
HAS ADAMAX BEEN SHOWN TO LAST LONGER OR WORK BETTER THAN SEMAX?
No direct comparative study supporting those claims was identified for this article. A proposed chemical modification is a reason to investigate a molecule, not a substitute for measuring its behavior.
Claims about longer persistence would require stability or breakdown measurements. Claims about greater brain exposure would require appropriate distribution studies. Claims about stronger biological activity would require clearly defined outcomes and direct comparisons under controlled conditions. The Semax papers summarized here do not answer those questions for ADAMAX.
HOW MUCH EVIDENCE COMES FROM HUMAN STUDIES?
The search for this article did not identify a published human study directly evaluating ADAMAX. Consequently, this review cannot establish its effects, safety, or long-term outcomes in people.
Research involving Semax or other related compounds cannot fill that gap. Each distinct compound requires evidence appropriate to its own identity and the claims being evaluated.
WHAT REMAINS UNCERTAIN?
The central research needs are reliable chemical characterization and experiments directly testing the identified material. Those would help establish whether proposed mechanisms, stability advantages, or biological effects can be reproduced.
Until such evidence is available, an accurate ADAMAX overview must distinguish proposed research questions from demonstrated results. The references below provide identification context and Semax background; none validates the safety, effectiveness, or performance of an ADAMAX product.
REFERENCES
[1] Medsafe. Classification of Unscheduled Peptides. Submission to the Medicines Classification Committee. June 2025. Identification context only; not an ADAMAX experimental study.
https://www.medsafe.govt.nz/profs/class/Agendas/Agen74/5.7Peptides.pdf
[2] Dolotov OV, Karpenko EA, Inozemtseva LS, et al. Semax, an analog of ACTH(4–10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus. Brain Research. 2006;1117(1):54–60. Semax study; not ADAMAX.
https://doi.org/10.1016/j.brainres.2006.07.108
[3] Sciacca MFM, Naletova I, Giuffrida ML, Attanasio F. Semax, a Synthetic Regulatory Peptide, Affects Copper-Induced Abeta Aggregation and Amyloid Formation in Artificial Membrane Models. ACS Chemical Neuroscience. 2022;13(4):486–496. Semax study; not ADAMAX.
https://doi.org/10.1021/acschemneuro.1c00707